{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:23:35Z","timestamp":1770963815901,"version":"3.50.1"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":4175,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1111\/j.1538-7836.2011.04369.x","type":"journal-article","created":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T06:14:27Z","timestamp":1311920067000},"page":"2-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"S1","title":["Gene therapy for haemophilia: a long and winding road"],"prefix":"10.1016","volume":"9","author":[{"given":"K.A.","family":"HIGH","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0010","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte\u2010directed gene therapy for ADA\u2010 SCID: initial trial results after 4\u2003years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0020","unstructured":"AMT submits its lead product Glybera\u00ae application for marketing authorisation to EMA. Press Release2010. http:\/\/investors.amtpharma.com\/phoenix.zhtml?c=212989&p=irol\u2010mediaArticle&ID=1373195&highlight=. Accessed 13 June 2011."},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0025","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X\u2010linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0030","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0035","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno\u2010associated virus gene vector: short\u2010term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0040","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age\u2010dependent effects of RPE65 gene therapy for Leber\u2019s congenital amaurosis: a phase 1 dose\u2010escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0045","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2\u2010associated clonal T cell proliferation in two patients after gene therapy for SCID\u2010X1","volume":"302","author":"Hacein\u2010Bey\u2010Abina","year":"2003","journal-title":"Science"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0050","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV\u2010factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease: progress and challenges","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat Rev Genet"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0060","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne\u2019s muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0065","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1538-7836.2009.03717.x","article-title":"Mild hemophilia A","volume":"8","author":"Franchini","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A","volume":"10","author":"Bi","year":"1995","journal-title":"Nat Genet"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0075","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood.V90.10.3962","article-title":"A coagulation factor IX\u2010deficient mouse model for human hemophilia B","volume":"90","author":"Lin","year":"1997","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0080","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1073\/pnas.94.21.11563","article-title":"A factor IX\u2010deficient mouse model for hemophilia B gene therapy","volume":"94","author":"Wang","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/vim.1996.9.141","article-title":"Adenovirus\u2010mediated transfer of human factor IX gene in immunodeficient and normal mice: evidence for prolonged stability and activity of the transgene in liver","volume":"9","author":"Yao","year":"1996","journal-title":"Viral Immunol"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0090","doi-asserted-by":"crossref","first-page":"10095","DOI":"10.1073\/pnas.86.24.10095","article-title":"Canine hemophilia B resulting from a point mutation with unusual consequences","volume":"86","author":"Evans","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0095","doi-asserted-by":"crossref","first-page":"12991","DOI":"10.1073\/pnas.192219599","article-title":"The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion","volume":"99","author":"Lozier","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0100","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1182\/blood.V88.9.3451.bloodjournal8893451","article-title":"A deletion mutation causes hemophilia B in Lhasa Apso dogs","volume":"88","author":"Mauser","year":"1996","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2141.2007.06942.x","article-title":"Gene therapy for haemophilia","volume":"140","author":"Murphy","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0110","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/gt.2008.71","article-title":"AAV\u2010mediated gene transfer for the treatment of hemophilia B: problems and prospects","volume":"15","author":"Hasbrouck","year":"2008","journal-title":"Gene Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0115","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2003-01-0167","article-title":"Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion","volume":"102","author":"Powell","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0120","doi-asserted-by":"crossref","first-page":"10379","DOI":"10.1073\/pnas.96.18.10379","article-title":"Long\u2010term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII\u2010deficient mice","volume":"96","author":"VandenDriessche","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0125","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood-2002-10-3050","article-title":"Neonatal or hepatocyte growth factor\u2010potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B","volume":"101","author":"Xu","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0130","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJM200106073442301","article-title":"Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A","volume":"344","author":"Roth","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0135","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1172\/JCI28416","article-title":"Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high\u2010titer inhibitory antibodies","volume":"116","author":"Shi","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0140","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1182\/blood-2004-12-4701","article-title":"Intracellular interaction of von Willebrand factor and factor VIII depends on cellular context: lessons from platelet\u2010expressed factor VIII","volume":"105","author":"Yarovoi","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0145","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1182\/blood-2010-06-293308","article-title":"In vivo efficacy of platelet\u2010delivered, high specific activity factor VIII variants","volume":"116","author":"Greene","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0150","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2174\/156652309789753310","article-title":"Progress towards liver and lung\u2010directed gene therapy with helper\u2010dependent adenoviral vectors","volume":"9","author":"Brunetti\u2010Pierri","year":"2009","journal-title":"Curr Gene Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/mt.2008.257","article-title":"Efficient, long\u2010term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates","volume":"17","author":"Brunetti\u2010Pierri","year":"2009","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0160","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/s-0037-1614984","article-title":"The canine factor VIII cDNA and 5\u2032 flanking sequence","volume":"79","author":"Cameron","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0165","doi-asserted-by":"crossref","first-page":"14082","DOI":"10.1073\/pnas.93.24.14082","article-title":"Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein","volume":"93","author":"Kessler","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0170","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1128\/jvi.70.11.8098-8108.1996","article-title":"Efficient long\u2010term gene transfer into muscle tissue of immunocompetent mice by adeno\u2010associated virus vector","volume":"70","author":"Xiao","year":"1996","journal-title":"J Virol"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0175","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1073\/pnas.94.11.5804","article-title":"Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno\u2010associated virus","volume":"94","author":"Herzog","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/4743","article-title":"Long\u2010term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno\u2010associated viral vector","volume":"5","author":"Herzog","year":"1999","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0185","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/mthe.2001.0442","article-title":"Muscle\u2010directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation","volume":"4","author":"Herzog","year":"2001","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0190","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1089\/104303402760128513","article-title":"Influence of vector dose on factor IX\u2010specific T and B cell responses in muscle\u2010directed gene therapy","volume":"13","author":"Herzog","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0195","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood-2003-05-1446","article-title":"Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno\u2010associated viral vector serotype 1","volume":"103","author":"Arruda","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0200","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCULATIONAHA.105.534008","article-title":"Uniform scale\u2010independent gene transfer to striated muscle after transvenular extravasation of vector","volume":"112","author":"Su","year":"2005","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0205","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1182\/blood-2009-12-261156","article-title":"Peripheral transvenular delivery of adeno\u2010associated viral vectors to skeletal muscle as a novel therapy for hemophilia B","volume":"115","author":"Arruda","year":"2010","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1111\/j.1538-7836.2011.04369.x_bb0210","first-page":"S126","article-title":"Safety and feasibility of transvenous limb perfusion with saline in human muscular dystrophy","volume":"18","author":"Powers","year":"2010","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0215","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/73464","article-title":"Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector","volume":"24","author":"Kay","year":"2000","journal-title":"Nat Genet"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0220","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV\u2010mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0225","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/4751","article-title":"Correction of hemophilia B in canine and murine models using recombinant adeno\u2010associated viral vectors","volume":"5","author":"Snyder","year":"1999","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0230","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.V99.8.2670","article-title":"Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver\u2010directed gene therapy","volume":"99","author":"Mount","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0235","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0240","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T\u2010cell responses to adeno\u2010associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0245","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI36891","article-title":"Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno\u2010associated viral vectors","volume":"119","author":"Pien","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0250","doi-asserted-by":"crossref","first-page":"10770","DOI":"10.1073\/pnas.0902269106","article-title":"Cellular immune response to cryptic epitopes during therapeutic gene transfer","volume":"106","author":"Li","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0255","unstructured":"Report on immune responses to adeno\u2010associated virus (AAV) vectors. Office of Biotechnology Activities, NIH Recombinant DNA Advisory Committee Meeting, June 19, 2007. 2007. http:\/\/oba.od.nih.gov\/rdna_rac\/rac_meetings.html. Accessed 13 June 2011."},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0260","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nm1445","article-title":"Heparin binding directs activation of T cells against adeno\u2010associated virus serotype 2 capsid","volume":"12","author":"Vandenberghe","year":"2006","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0265","unstructured":"Gene transfer for subjects with hemophilia B factor IX deficiency. Clinical Trials.gov Identifier: NCT00515710. 2007. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00515710?term=Hemophilia+B+AND+ Philadelphia&rank=1. Accessed 13 June 2011."},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0270","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV\u2010mediated gene transfer to liver","volume":"110","author":"Mingozzi","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0275","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosissup.2010.03.004","article-title":"Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency","volume":"11","author":"Gaudet","year":"2010","journal-title":"Atheroscler Suppl"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0280","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno\u2010associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0285","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/sj.gt.3302134","article-title":"Adeno\u2010associated virus terminal repeat (TR) mutant generates self\u2010complementary vectors to overcome the rate\u2010limiting step to transduction in vivo","volume":"10","author":"McCarty","year":"2003","journal-title":"Gene Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0290","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self\u2010complementary adeno\u2010associated virus vectors containing a novel liver\u2010specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0295","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood.V116.21.248.248","article-title":"Early clinical trial results following administration of a low dose of a novel self complementary adeno\u2010associated viral vector encoding human Factor IX in two subjects with severe hemophilia B","volume":"116","author":"Nathwani","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0300","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno\u2010associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0305","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/S1525-0016(16)37175-1","article-title":"Dose\u2010dependent activation of capsid\u2010specific T cells after AAV serotype 8 vector administration in a clinical study for hemophilia","volume":"19","author":"Basner\u2010Tschakarjan","year":"2011","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0310","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/mt.2011.13","article-title":"Hemophilia gene therapy: a holy grail found","volume":"19","author":"Ponder","year":"2011","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0315","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.V116.21.250.250","article-title":"Stable high level coagulation Factor VIII expressin in vivo follwing gene transfer using a novel expression cassette encoding a more potent FVIII variant","volume":"116","author":"McIntosh","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0320","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X\u2010linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0325","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","article-title":"Codon optimization of human factor VIII cDNAs leads to high\u2010level expression","volume":"117","author":"Ward","year":"2011","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0330","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0335","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood-2010-08-302729","article-title":"Assessing the potential for AAV vector genotoxicity in a murine model","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"Suppl. 4","key":"10.1111\/j.1538-7836.2011.04369.x_bb0340","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2516.2004.00997.x","article-title":"Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia","volume":"10","author":"Goedert","year":"2004","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0345","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.1840200104","article-title":"Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group","volume":"20","year":"1994","journal-title":"Hepatology"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0350","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.79.17.11434-11442.2005","article-title":"Large\u2010scale analysis of adeno\u2010associated virus vector integration sites in normal human cells","volume":"79","author":"Miller","year":"2005","journal-title":"J Virol"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0355","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/JVI.79.6.3606-3614.2005","article-title":"Large\u2010scale molecular characterization of adeno\u2010associated virus vector integration in mouse liver","volume":"79","author":"Nakai","year":"2005","journal-title":"J Virol"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0360","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.gt.3301541","article-title":"Observed incidence of tumorigenesis in long\u2010term rodent studies of rAAV vectors","volume":"8","author":"Donsante","year":"2001","journal-title":"Gene Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0365","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1016\/S1525-0016(16)37396-8","article-title":"Factor IX expressoin in muscle of a severe hemophilia B patient 10\u2003years after AAV gene transfer","volume":"19","author":"Buchlis","year":"2011","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0370","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ymthe.2006.05.004","article-title":"Evidence of multiyear factor IX expression by AAV\u2010mediated gene transfer to skeletal muscle in an individual with severe hemophilia B","volume":"14","author":"Jiang","year":"2006","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0375","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2003-05-1498","article-title":"Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune\u2010tolerant hemophilia B dogs","volume":"102","author":"Russell","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0380","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/blood-2003-05-1519","article-title":"Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment","volume":"102","author":"Yarovoi","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0385","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1538-7836.2007.02346.x","article-title":"Lentivirus\u2010mediated platelet\u2010derived factor VIII gene therapy in murine haemophilia A","volume":"5","author":"Shi","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0390","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/j.1538-7836.2008.02992.x","article-title":"Platelet\u2010delivered factor VIII provides limited resistance to anti\u2010factor VIII inhibitors","volume":"6","author":"Gewirtz","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0395","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1182\/blood-2008-02-138214","article-title":"Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity","volume":"112","author":"Shi","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0400","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2008-04-152959","article-title":"Analysis of the spatial and temporal characteristics of platelet\u2010delivered factor VIII\u2010based clots","volume":"112","author":"Neyman","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0405","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/nbt1227","article-title":"Stem cell\u2010derived erythroid cells mediate long\u2010term systemic protein delivery","volume":"24","author":"Chang","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0410","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1172\/JCI20106","article-title":"Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII","volume":"113","author":"Margaritis","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0415","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1172\/JCI32878","article-title":"Long\u2010term expression of murine activated factor VII is safe, but elevated levels cause premature mortality","volume":"118","author":"Aljamali","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0420","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood-2008-07-168377","article-title":"Successful treatment of canine hemophilia by continuous expression of canine FVIIa","volume":"113","author":"Margaritis","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0425","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2010-09-309732","article-title":"Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo","volume":"117","author":"Margaritis","year":"2011","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0430","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver\u2010restricted promoter facilitates sustained expression of therapeutic levels of alpha\u2010galactosidase A and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0435","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1073\/pnas.95.10.5734","article-title":"Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A","volume":"95","author":"Evans","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0440","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy","volume":"116","author":"Finn","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0445","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature03556","article-title":"Highly efficient endogenous human gene correction using designed zinc\u2010finger nucleases","volume":"435","author":"Urnov","year":"2005","journal-title":"Nature"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0450","doi-asserted-by":"crossref","unstructured":"Li H, Haurigot V, Doyon Y, Li J, Bhagwat A, Wong S, Anguela X, Sharma R, Ivanciu L, Murphy S, Zhou Z, Paschon D, Rebar E, Gregory PD, Holmes MC, High KA. Phenotypic Correction of a Mouse Model of Hemophilia B by In Vivo Genetic Correction of the F9 Gene. 52nd ASH Annual Meeting and Exposition. Orlando, FL, 2010.","DOI":"10.1182\/blood.V116.21.LBA-5.LBA-5"},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0455","unstructured":"Autologous T\u2010cells genetically modified at the CCR5 gene by zinc finger nucleases SB\u2010728 for HIV (Zinc\u2010Finger). Clinical Trials.gov Identifier: NCT00842634. 2009. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00842634?term=Zinc+Finger&rank=1. Accessed 13 June 2011."},{"key":"10.1111\/j.1538-7836.2011.04369.x_bb0460","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1089\/hum.2005.16.811","article-title":"Sustained phenotypic correction of canine hemophilia B after systemic administration of helper\u2010dependent adenoviral vector","volume":"16","author":"Brunetti\u2010Pierri","year":"2005","journal-title":"Hum Gene Ther"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2011.04369.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622055416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622055416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2011.04369.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:57:01Z","timestamp":1761533821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622055416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":91,"alternative-id":["S1538783622055416"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04369.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for haemophilia: a long and winding road","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04369.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}